Pulmonary Arterial Hypertension

The Social Security Administration (SSA) uses a screening tool called the Listing of Impairments to identify claimants who are so severely impaired that they cannot work at all and thus immediately qualify for benefits. In this report, the IOM makes several recommendations for improving SSA's capacity to determine disability benefits more quickly and efficiently using the Listings.

This book focuses on pulmonary arterial hypertension (PAH, Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, Group 4) among the various groups of pulmonary hypertension (PH) whose classification was updated into five major categories at the 5th World Symposium held in Nice, France, in 2013. Readers will find recent progress, methods, and up-to-date information on PH mechanisms, diagnostic images, and treatment in the management of PH.This volume, with contributions by leading researchers worldwide in the field , consists of five parts, starting with the fundamentals of PH, then pathophysiology and genetics, treatment, and right ventricular function.

This book is a clinical guide to controversial and emerging topics in pulmonary hypertension. There are multiple challenges and unanswered questions encountered by clinicians that evaluate, diagnose and treat patients with suspected or confirmed pulmonary vascular disease. This book provides a deep dive into the diagnosis and therapeutics of pulmonary hypertension supported by the literature and balanced with personal clinical experience. Expert authors have chosen these specific topics to address issues where uncertainty and/or controversy exists as well as highlight areas that are just being incorporated into clinical practice. These topics include: exercise pulmonary hypertension, sickle cell disease and pulmonary hypertension, and sarcoid pulmonary hypertension, among many others. Chapters address the diagnostic and treatment dilemmas posed by these various clinical entities through literature review, sharing of expert opinion, and review of recent guidelines and their applicability to the multiple different nuanced presentations of pulmonary hypertension. This is an ideal guide for pulmonologists, cardiologists, and other specialty practitioners caring for patients with pulmonary hypertension.

This open access book focuses on the molecular mechanism of congenital heart disease and pulmonary hypertension, offering new insights into the development of pulmonary circulation and the ductus arteriosus. It describes in detail the molecular mechanisms involved in the development and morphogenesis of the heart, lungs and ductus arteriosus, covering a range of topics such as gene functions, growth factors, transcription factors and cellular interactions, as well as stem cell engineering technologies. The book also presents recent advances in our understanding of the molecular mechanism of lung development, pulmonary hypertension and molecular regulation of the ductus arteriosus. As such, it is an ideal resource for physicians, scientists and investigators interested in the latest findings on the origins of congenital heart disease and potential future therapies involving pulmonary circulation/hypertension and the ductus arteriosus.

Pulmonary arterial hypertension (PAH) is a high blood pressure in the arteries that supply the lungs with blood. Patients with mild PAH, particularly young patients, may feel quite well and get breathless or tired only with vigorous exertion. Those with severe PAH may get breathless on minimal exertion and feel tired, exhausted and experience chest pain, forceful heart beats, dizzy turns, loss of appetite, and have swelling of the legs due to fluid retention. This book will help patients and their families understand what PAH is, and advise them on how to cope with their illness. In the UK patients with PAH are referred to one of the eight National Pulmonary Hypertension centres staffed by a team of specialist doctors, nurses, pharmacists, and other staff who are experienced and expert in managing all aspects of the condition. Currently, the drugs used to treat the condition can be prescribed only by these specialists. The book will explain what the illness is and how it is treated in a reassuring and understandable way. The book will also be of interest to GPs, nurses and other related healthcare professionals.

​This title will be presented as highly practical information on pharmaceutical options in pulmonary hypertension, written in a quick-access, no-nonsense format. The emphasis will be on a just-the-facts clinical approach, heavy on tabular material, light on dense prose. The involvement of the ISCP will ensure that the best quality contributors will be involved and establish a consistent approach to each topic in the series. Each volume is designed to be between 100 and 150 pages containing practical illustrations and designed to improve understand and practical usage of cardiovascular drugs in specific clinical areas.​

Pulmonary hypertension is a fatal lung and heart disease. It is characterized by shortness of breath, fatigue and fainting. It is exacerbated by an increase of the pressure in the lung vasculature through exercise, leading to progressive worsening of hemodynamics, right ventricular hypertrophy, right heart insufficiency and finally right heart failure. This book focuses on pulmonary arterial hypertension, a rare and progressive subgroup of pulmonary hypertension, which is today incurable and terminally faal. Classification of pulmonary arterial hypertension, its pathology, and strategies for future therapy will be of interest both to those suffering from the disease and those who take care of patients. This volume will also engage physicians and other scientists contributing to an understanding of the pathophysiology of pulmonary arterial hypertension and attempting to extend life of humans with pulmonary arterial hypertension by developing causal and curative therapies.

This book explains the pharmacological relationships between the various systems in the human body. It offers a comprehensive overview of the pharmacology concerning the autonomic, central, and peripheral nervous systems. Presenting up-to-date information on chemical mediators and their significance, it highlights the therapeutic aspects of several diseases affecting the cardiovascular, renal, respiratory, gastrointestinal, endocrinal, and hematopoietic systems. The book also includes drug therapy for microbial and neoplastic diseases. It also comprises sections on immunopharmacology, dermatological, and ocular pharmacology providing valuable insights into these emerging and recent topics. Covering the diverse groups of drugs acting on different systems, the book reviews their actions, clinical uses, adverse effects, interactions, and subcellular mechanisms of action. It is divided into 11 parts, subdivided into several chapters that evaluate the basic pharmacological principles that govern the different types of body systems. This book is intended for academicians, researchers, and clinicians in industry and academic institutions in pharmaceutical, pharmacological sciences, pharmacy, medical sciences, physiology, neurosciences, biochemistry, molecular biology and other allied health sciences.